AIFF Overview

Firefly Neuroscience, Inc. is an artificial intelligence (AI) company advancing precision neuroscience. The Company's BNA Platform and Evoke System are Class II medical devices, which were cleared by FDA for commercialization. The Company's FDA-510(k) cleared Evoke System, commercially deployed as the Evoke System, is in active use over 85 clinical sites in the United States. The Company has developed Firefly Platform, a vertically integrated hardware, software, and data infrastructure that captures standardized electroencephalographic (EEG) and event-related potential (ERP) assessments at the point of care, analyzes that data through its proprietary analytics engine, and delivers structured, clinician-ready reports back to the provider, all within a single seamless workflow. Its proprietary analytics engine analyzes raw EEG and ERP signals across captured dimensions and compares each patient’s electrophysiological profile to a reference dataset.

Wall Street analysts forecast AIFF stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AIFF is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Firefly Neuroscience Inc revenue for the last quarter amounts to 412.00K USD, increased 677.36

Firefly Neuroscience Inc. EPS for the last quarter amounts to -0.20 USD, decreased -53.49

Firefly Neuroscience Inc (AIFF) has 17 emplpoyees as of April 16 2026.

Today AIFF has the market capitalization of 23.37M USD.